Host: Bruce Japsen 


  Guest: Vincent Bufalino, MD 



  
    Patients and doctors are becoming more aware of tools like Web-based risk assessment for heart disease for reaching and potentially helping thousands of people. But how can the success of these efforts be increased? Dr. Vincent Bufalino, CEO of Midwest Heart Specialists, one of the biggest community cardiac physician groups in the country, tells host Bruce Japsen about ways to get patients to use online risk assessments and how doctors can successfully integrate them into their practices as a life-saving tool.

Integrating Online Heart Disease Risk Assessments into Practice

In this special series, ReachMD examines the reasons behind the dropping rates of death from heart disease: more effective medications, smarter technologies, more efficient treatment guidelines and much more.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Host: William Boden, MD, FACC, FAHA 



  
    Patients with ASCVD and a history of MI are at especially high risk for repeat adverse cardiac events. Listen in as Dr. Bill Boden summarizes a post hoc analysis of such patients from the REDUCE-IT trial. Can icosapent ethyl plus a statin provide improved carioprotection by reducing recurrent events in this population? Tune in to learn more! REDUCE-IT is a landmark trial that examined the coadministration of icosapent ethyl and statins in patients for secondary and primary prevention of recurrent events and demonstrated a significant reduction in the key primary and secondary endpoints. This discussion relates to a post hoc analysis of a subset of patients who had prior myocardial infarction, as part of the REDUCE-IT study, and comprised about 45% of the patients with established atherosclerotic coronary disease. The results of this post-MI analysis bring into clear focus that treating hypertriglyceridemia is a critical variable in terms of reducing dyslipidemic risk and overall risk.

Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction with Icosapent Ethyl in Post-MI Patients: Key Takeaways

Host: Mikhail Kosiborod, MD 


  Guest: Michael Böhm, MD, FESC 



  
    The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.

The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over?

Host: Marco Metra, MD 


  Guest: Adrian F. Hernandez, MD, MHS 



  
    Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.

From Paper to Patient: Applying Guideline Updates to Practice

Host: Matt Birnholz, MD 


Guest: William Gray, MD 



  When compared to the options available to coronary artery disease patients, advances in treatment for peripheral artery disease have unfortunately been lacking. But now that’s all changing with the introduction of drug-eluting stents as a treatment option, as explained by the President of Lankenau Heart Institute at Main Line Health Dr. William Gray. 

Peripheral Artery Disease: How New Stent Options Are Revolutionizing Care

Host: Peter Libby, MD 


Host: Michael Miller, MD, FACC, FAHA, FNLA 


Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC 


Guest: R. Preston Mason, PhD 


Guest: Børge G. Nordestgaard, MD, DMSc 



  This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include:  Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy Biologic Basis for TGRL Modulation in Reducing Atherosclerosis Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT  For more information, contact Medtelligence, LLC at info@medtelligence.net.

Integrating Online Heart Disease Risk Assessments into Practice

Download our free app to listen on your phone